HC Wainwright reaffirmed their buy rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a research note published on Friday morning, Benzinga reports. HC Wainwright currently has a $16.00 target price on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on the stock. StockNews.com cut shares of Ocular Therapeutix […]
JMP Securities restated their market outperform rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a $24.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a buy […]
Recursion, Canaan, Metsera and more—Chutes & Ladders fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with.
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.